14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CING vs AZN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, AstraZeneca PLC (AZN) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas AZN carries 44.8/100 (HOLD) at $182.62 (16.3x Forward P/E, 25.8% operating margin).
Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.9); meanwhile AZN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs AZN. Trailing 12-month operating profitability (CING 0.0% vs AZN 25.8%) and valuation multiples (CING N/M vs AZN 16.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
AZN Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $286.1B market capitalization and 25.8% operating margin.
OpEx & R&D Reinvestment56.0% of Rev ($34.9B)
90D Engineering Disclosures0 Published
Investor FAQ CING vs AZN Key Questions & Quantitative Answers
As of Nov 17, 2026, AstraZeneca PLC (AZN) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas AZN carries 44.8/100 (HOLD) at $182.62 (16.3x Forward P/E, 25.8% operating margin). Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.9); meanwhile AZN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AZN leads the Growth & Scale pillar: CING posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AZN at +6.7% YoY revenue growth and +23.5% YoY earnings growth on $62.4B TTM revenue (81.8% gross margin, 25.8% operating margin). On trailing 12-month operating scale, CING generates N/A in USD-normalized revenue versus $62.4B for AZN. In operating R&D and SG&A reinvestment, CING deploys N/A (0 90-day corporate R&D disclosures) versus 56.0% of Rev ($34.9B) (0 disclosures) for AZN.
AZN screens cheaper on headline valuation multiples. CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AZN trades at 16.3x Forward P/E, 26.1x Trailing P/E, 1.33x PEG, and 4.6x EV/Revenue (34.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CING (-198.7% ROE) versus AZN (22.6% ROE) capital efficiency.
In options market volatility and institutional positioning, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk). By comparison, AZN carries 20.3% implied volatility (8th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.04β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.